<DOC>
	<DOCNO>NCT01749462</DOCNO>
	<brief_summary>The purpose investigation confirm ADR development contribute factor possibly impact safety post-marketing actual use Oxis 9 mcg Turbuhaler .</brief_summary>
	<brief_title>Oxis 9mcg Turbuhaler Clinical Experience Investigation</brief_title>
	<detailed_description>Oxis 9mcg Turbuhaler Clinical Experience Investigation</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Patients treat Oxis first time due 'relief various symptom associate airway obstructive disorder chronic obstructive pulmonary disease ( Chronic bronchitis , Pulmonary emphysema ) , indication drug .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>chronic obstructive pulmonary disease ,</keyword>
	<keyword>COPD ,</keyword>
	<keyword>Oxis ,</keyword>
</DOC>